This is a continuation of an existing, well-functioning, and absolutely essential Core. Over its lifetime, Core A (National Tissue Resource) has provided a very large number of tissues to SPORE and non-SPORE investigators alike, nationally and even internationally. During our first 9 years, from 1993 through 2001, a total of 10,866 tumor samples were delivered to 78 projects. Investigators in this SPORE accounted for only about 40% of that activity ? more than 6,000 specimens were provided to 59 different investigators outside the SPORE. Since the last submission (2002 to 2006), the Core has provided 5,057 specimens (with an additional 1320 pending distribution) to 34 projects involving 17 different principal investigators. A large fraction of distributions continue to go to investigators outside of our own SPORE. At least 25 full length manuscripts directly related to use of specimens and/or data from our SPORE tissue resources have been published since the last submission. The continuing objectives of the National Tissue Resource Core are to provide centralized support for tissue banking, quality assessment, and distribution efforts within the Breast SPORE by managing and distributing tissue and data from legacy inventories to qualified researchers;by collecting, managing, and distributing newly acquired breast cancer materials to qualified researchers;by assisting in acquisition, management, and distribution of clinical trial associated material;and by collection of additional clinical and follow-up data on appropriately consented subjects represented in the collections. Although guidelines state that """"""""each SPORE must have a dedicated core for collection and distribution of human cancer specimens"""""""", Core A greatly surpasses this minimum requirement ? it is critical for the research activities resource to other scientists within and outside Baylor College of Medicine who are engaged in translational breast cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Holloway, Kimberly R; Sinha, Vidya C; Bu, Wen et al. (2016) Targeting Oncogenes into a Defined Subset of Mammary Cells Demonstrates That the Initiating Oncogenic Mutation Defines the Resulting Tumor Phenotype. Int J Biol Sci 12:381-8
Malorni, Luca; Giuliano, Mario; Migliaccio, Ilenia et al. (2016) Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res 14:470-81
Fu, Xiaoyong; Jeselsohn, Rinath; Pereira, Resel et al. (2016) FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A 113:E6600-E6609
Erdem, Cemal; Nagle, Alison M; Casa, Angelo J et al. (2016) Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways. Mol Cell Proteomics 15:3045-57
Chaluvally-Raghavan, Pradeep; Jeong, Kang Jin; Pradeep, Sunila et al. (2016) Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15:1493-1504
Dobrolecki, Lacey E; Airhart, Susie D; Alferez, Denis G et al. (2016) Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35:547-573
Shi, Aiping; Dong, Jie; Hilsenbeck, Susan et al. (2015) The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One 10:e0132214
Canfield, Kaleigh; Li, Jiaqi; Wilkins, Owen M et al. (2015) Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle 14:648-55
Sine, Jessica; Urban, Cordula; Thayer, Derek et al. (2015) Photo activation of HPPH encapsulated in ""Pocket"" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine 10:125-45

Showing the most recent 10 out of 295 publications